FDA pushes for ethnic diversity in clinical trials
This September more than 6,000 patients were prescribed medical marijuana treatment through the country’s SAS Category B pathway. This was the highest gain per month ever since the 2016, and it was 18% higher than August of this year, although admittedly the market remains quite small.
Nonetheless there’s noticeable progress and according to North Sydney-based data FreshLeaf Analytics predict that the Australian medical cannabis market will rise to about 95 million Australian dollars in sales of products by 2021.
Also, since currently the products imported from overseas are required to conform with a local law order, they are not always required to be manufactured in a Good Manufacturing Practice-licensed facility, and so the Australian Government is considering mandating that imported medical marijuana meet the GMP quality standards. The Health Department is expected to release consultations on increasing quality requirements for imported cannabis products towards the end of the year.
Royal College of Surgeons and the National College of Art and Design partner to develop a silicone heart model